Kuros Biosciences AG/€KURN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Kuros Biosciences AG
Kuros Biosciences AG is a biotechnology company based in Switzerland, focused on the development of products for tissue repair and regeneration. Core to its business are biomaterial-based products designed to support bone healing in specific medical conditions. Its product portfolio includes innovative solutions like MagnetOs, used for spinal fusion; it is designed to enhance the body’s natural bone healing process. The company, headquartered in Schlieren, Switzerland, leverages its proprietary technologies to target significant unmet medical needs, positioning itself in the niche market of orthobiologics. Kuros Biosciences emphasizes innovation in biologics and synthetic solutions, aiming for a competitive edge in the healthcare sector.
Ticker
€KURN
Sector
Primary listing
XGAT
Employees
158
Headquarters
Schlieren, Switzerland
Website
KURN Metrics
BasicAdvanced
€978M
-
-€0.14
0.61
-
Price and volume
Market cap
€978M
Beta
0.61
52-week high
€34.16
52-week low
€14.93
Average daily volume
92K
Financial strength
Current ratio
2.251
Quick ratio
1.679
Long term debt to equity
1.485
Total debt to equity
2.337
Interest coverage (TTM)
0.72%
Profitability
EBITDA (TTM)
6.244
Gross margin (TTM)
88.70%
Net profit margin (TTM)
-5.87%
Operating margin (TTM)
3.73%
Effective tax rate (TTM)
-22.34%
Revenue per employee (TTM)
€696,850
Management effectiveness
Return on assets (TTM)
2.57%
Return on equity (TTM)
-8.62%
Valuation
Price to revenue (TTM)
10.392
Price to book
12.41
Price to tangible book (TTM)
27.29
Price to free cash flow (TTM)
-1,598.309
Free cash flow yield (TTM)
-0.06%
Free cash flow per share (TTM)
-0.016
Growth
Revenue change (TTM)
83.30%
Earnings per share change (TTM)
-54.63%
3-year revenue growth (CAGR)
89.64%
3-year earnings per share growth (CAGR)
-26.18%
Bulls say / Bears say
Strong H1 2025 revenue growth: Total Medical Device sales increased 78% to USD 63.5 million in H1 2025, demonstrating strong market demand for MagnetOs (GlobeNewswire)
First operating profit: The Group delivered an operating profit of USD 3.5 million in H1 2025, compared to an operating loss of USD 0.2 million a year earlier (GlobeNewswire)
Strategic U.S. expansion through Medtronic partnership: Kuros signed a five-year exclusive sales agency agreement with Medtronic for MagnetOs in key U.S. spine markets, expanding distribution reach (Kuros Press Release)
Continuing net loss: Despite improved operations, Kuros posted a net loss of USD 2.0 million in H1 2025, highlighting ongoing profitability issues (GlobeNewswire)
Rising operating costs: General and administrative expenses grew to USD 11.1 million in H1 2025 from USD 7.8 million in H1 2024, putting pressure on margins (GlobeNewswire)
Slight cash depletion: Cash and cash equivalents were USD 18.4 million as of June 30, 2025, down from USD 19.8 million at December 31, 2024, potentially limiting near-term financial flexibility (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kuros Biosciences AG stock?
Kuros Biosciences AG (KURN) has a market cap of €978M as of September 18, 2025.
What is the P/E ratio for Kuros Biosciences AG stock?
The price to earnings (P/E) ratio for Kuros Biosciences AG (KURN) stock is 0 as of September 18, 2025.
Does Kuros Biosciences AG stock pay dividends?
No, Kuros Biosciences AG (KURN) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Kuros Biosciences AG dividend payment date?
Kuros Biosciences AG (KURN) stock does not pay dividends to its shareholders.
What is the beta indicator for Kuros Biosciences AG?
Kuros Biosciences AG (KURN) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.